pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia
Elan Pharmaceuticals
Elan Pharma International
Elan Pharmaceuticals clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Treasury Building, Lower Grand Canal Street, Dublin 2, IE
- Founded
- 1969
- Employees
- 792
- Programs
- 18
- Drugs
- 26
- Patents
- 0
Elan Pharmaceuticals projects
9 ClinicalTrials.gov programs sponsored by Elan Pharmaceuticals.
Elan Pharmaceuticals has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Fipaxalparant
Elan Pharma International
Diffuse Cutaneous Systemic Sclerosis
1 trial -
GH001-TRD-201
Elan Pharma International
Treatment-resistant depression (TRD)
1 trial -
HZNP-DAX-202
Elan Pharma International
Primary Discoid Lupus Erythematosus
1 trial -
HZNP-HZN-1116-201
Elan Pharma International
Sjögren’s Syndrome
1 trial -
HZNP-HZN-825-301
Elan Pharma International
Diffuse Cutaneous Systemic Sclerosis
1 trial -
HZNP-HZN-825-303
Elan Pharma International
Idiopathic Pulmonary Fibrosis
1 trial -
INEBILIZUMAB
Elan Pharma International
Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])
1 trial -
TMC435
Elan Pharma International
Hepatitis C
1 trial -
WVE-006
Elan Pharma International
Alpha-1 antitrypsin deficiency (AATD)
1 trial
Frequently asked questions
How many clinical projects does Elan Pharmaceuticals have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.